--- title: "Newron Pharmaceuticals to participate in H.C. Wainwright 28th Annual Global Investment Conference, Milan, Italy and Morristown, NJ; CEO to present Sept 16, 2026" sdDatePublished: "2026-09-03T11:07:00Z" source: "https://www.newron.com/news-and-media/regulatory-news/newron-pharmaceuticals-participate-hc-wainwright-28th-annual-global" topics: - name: "pharmaceutical" identifier: "medtop:20000223" - name: "business information" identifier: "medtop:20000170" - name: "business strategy and marketing" identifier: "medtop:20000192" - name: "medical research" identifier: "medtop:20000737" locations: - "Milan" - "Italy" - "United States" - "Israel" - "Switzerland" - "United Kingdom" - "Australia" - "Japan" - "United Arab Emirates" - "South Korea" - "Canada" --- Newron Pharmaceuticals to participate in H.C. Wainwright 28th Annual Global Investment Conference, Milan, Italy and Morristown, NJ; CEO to present Sept 16, 2026 Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference | Newron Pharmaceuticals Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference Milan, Italy, and Morristown, NJ, USA, September 3, 2026 , – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber , Chief Executive Officer, will participate in the H.C. Wainwright 28 th Annual Global Investment Conference: H.C. Wainwright 28th Annual Global Investment Conference Format: Company presentation and one-on-ones Presentation Date: Wednesday, September 16, 2026, at 11:00 AM ET Presenter: Stefan Weber, Chief Executive Officer, Newron Please contact a conference representative to request one-on-one meetings, or please contact John Fraunces at [email protected] . Note that the Company presentation will be accessible on the News and Events page of the Newron website ( www.newron.com ). Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently being developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago® safinamide received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: www.newron.com and connect with us on LinkedIn . For more information, please contact: Stefan Weber – CEO; [email protected] Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, [email protected] Valentin Handschin, IRF; +41 43 244 81 54, [email protected] Maximilian Schur, MC Services; +49 211 52925227, [email protected] John Fraunces, LifeSci Advisors, +1 917 355 2395 [email protected] Milan, Italy, and Morristown, NJ, USA, September 3, 2026 (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that will participate in the H.C. Wainwright 28 th Annual Global Investment Conference: Please contact a conference representative to request one-on-one meetings, or please contact John Fraunces at Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently being developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago® safinamide received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: and connect with us on Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, Valentin Handschin, IRF; +41 43 244 81 54, Maximilian Schur, MC Services; +49 211 52925227, John Fraunces, LifeSci Advisors, +1 917 355 2395 Investors Investors Reports and Presentations Share price Information Governance Shareholders' Meeting FAQs Email Alerts Investors Keep track of our business - This area contains investment and shareholder information Keep track of our business - This area contains investment and shareholder information News and Events News and Events Events News Adhoc news News and Events We provide regular updates on the progress being made. We provide regular updates on the progress being made. Contacts Contacts Work with us Contacts Newron is located in the north part of Milan in the new Bresso Bioscience Park about 45 minutes from Malpensa International Airport and 25 30 minutes from Linate city airport. Newron is located in the north part of Milan in the new Bresso Bioscience Park about 45 minutes from Malpensa International Airport and 25 30 minutes from Linate city airport. Newron Pharmaceuticals SpA via Antonio Meucci 3 20091 Bresso (Mi) Italy Tel +39 02 610 3461 E-mail: [email protected] Keep up to date on social media